Table 1.
Clinical parameters and cross-tabulation results for the QM, non-QM and unclassifiable cohorts. Abbreviations: pT: tumor T-stage, pN: nodal status, M: metastasis, G: histopathological grading, R: resection margins (All UICC 6th ed.), CA19-9 and CEA: Carbohydrate Antigen 19-9 and Carcinoembryonic Antigen, N.A.: Not available. Statistical tests used: 1: Chi-Squared-Test, 2: one-way ANOVA, 3: Log-Rank-Test. N.S.: Not significant at the two-sided level of p < 0.05.
| Variable | QM (n = 45) | Non-QM (n = 136) | Unclassifiable (n = 26) | p-Value | |
|---|---|---|---|---|---|
| Sex | Male Female |
25 (55%) 20 (45%) |
75 (55%) 61 (45%) |
14 (54%) 12 (46%) |
0.99 1 |
|
Age
(years) |
Mean Range |
68 42–87 |
67 45–90 |
72 53–90 |
0.84 2 |
| pT | T1 T2 T3 T4 |
1 (2%) 8 (18%) 31 (69%) 5 (11%) |
3 (2%) 19 (14%) 103 (76%) 11(8%) |
1(4%) 4 (15%) 18 (69%) 3 (12%) |
0.97 1 |
| pN | N0 N1 |
13 (29%) 32 (71%) |
31 (23%) 105 (77%) |
5 (19%) N1 (81%) |
0.60 1 |
| M | M0 M1 |
39 (87%) 6 (13%) |
125 (91%) 11 (8%) |
25 (96%) 1 (4%) |
0.36 1 |
| G | G1 G2 G3 |
1 (2%) 21 (47%) 23 (51%) |
6 (4%) 60 (45%) 70 (51%) |
4 (15%) 13 (50%) 9 (35%) |
0.11 1 |
| R | R0 R1 |
20 (44%) 25 (56%) |
68 (50%) 68 (50%) |
15 (58%) 11 (42%) |
0.56 1 |
| CA19-9 | Normal Elevated N.A. |
5 (10%) 20 (45%) 20 (45%) |
22 (16%) 43 (32%) 71 (52%) |
2 (8%) 5 (19%) 19 (73%) |
0.11 1 |
| CEA | Normal Elevated N.A. |
12 (27%) 8 (18%) 25 (55%) |
38 (27%) 12 (9%) 86 (64%) |
3 (11%) 1(4%) 22 (85) |
0.08 1 |
|
First-Line
Chemotherapy |
Gemcitabine FOLFIRINOX Did not receive |
16 (36%) 3 (7%) 26 (57%) |
68 (50%) 2 (2%) 66 (48%) |
12 (46%) 2 (8%) 12 (46%) |
0.16 1 |
| Median Overall Survival (months) | 9.5 | 16.5 | 14.6 | - QM vs. Non-QM: 0.03 3 - Others N.S. 3 |
|
| Censored | No Yes |
31 (69%) 14 (31%) |
97 (71%) 39 (29%) |
20 (77%) 6 (23%) |
0.77 1 |
| Tumor Location | Head/Body Tail |
44 (98%) 1 (2%) |
133 (98%) 3 (2%) |
25 (96%) 1 (4%) |
0.87 1 |